Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
23 Janeiro 2025 - 9:00AM
Business Wire
Conference Call and Webcast Scheduled for 1:30
p.m. PT
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical
and medical technology company focused on novel therapies for the
treatment of glaucoma, corneal disorders and retinal diseases,
plans to release fourth quarter and full year 2024 financial
results after the market close on Thursday, February 20, 2025. The
company’s management will discuss the results during a conference
call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on
February 20, 2025.
A link to the live webcast will be available on the company’s
website at http://investors.glaukos.com. To participate in the
conference call, please dial 888-210-2212 (U.S.) or 646-960-0390
(International) and enter Conference ID 7935742. A replay will be
archived on the company’s website following completion of the
call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and
medical technology company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012. In 2024, Glaukos commenced commercial
launch activities for iDose® TR, a first-of-its-kind,
long-duration, intracameral procedural pharmaceutical designed to
deliver 24/7 glaucoma drug therapy inside the eye for extended
periods of time. Glaukos also markets the only FDA-approved corneal
cross-linking therapy utilizing a proprietary bio-activated
pharmaceutical for the treatment of keratoconus, a rare corneal
disorder. Glaukos continues to successfully develop and advance a
robust pipeline of novel, dropless platform technologies designed
to meaningfully advance the standard of care and improve outcomes
for patients suffering from chronic eye diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250123829865/en/
Chris Lewis Vice President, Investor Relations and Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Glaukos (NYSE:GKOS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
